Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Cybin Inc (NY: CYBN ) 0.3034 -0.0116 (-3.68%) Streaming Delayed Price Updated: 1:54 PM EDT, Jul 17, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Cybin Inc < Previous 1 2 ... 14 15 16 17 18 19 20 21 Next > Cybin To Test Psychedelic-Assisted Psychotherapy For COVID-Related Distress November 30, 2021 The FDA authorized an investigator-initiated Phase 2 trial evaluating Cybin Inc's (NYSE: CYBN) psychedelic-assisted psychotherapy with psilocybin for... Via Benzinga Exposures Product Safety Cybin Supports Psychedelic Treatment Clinic Through Grant November 23, 2021 Cybin (NYSE: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced it has awarded a grant for the first... Via Benzinga NY's Lenox Hill Hospital With Cybin-Awarded Grant Will Provide Psychedelic Therapy To City's Underserved November 23, 2021 Psychedelic therapy company, Cybin Inc. (NEO: CYBN) (NYSE: Via Benzinga Psychedelic Drug Stocks Continued To Decline Last Week November 21, 2021 The 12 constituents in our Pure-Play Psychedelic Compounds-Based Drug Stocks Index declined -5.7% last week; it's now -16.1% so far in November. Via Talk Markets Cybin 'One Step Closer' to Creating Best Therapy for Mental Health November 19, 2021 Company releases positive results from a pre-clinical study focusing on psilocybin program CYB003 Multiple academic studies have shown that psilocybin may have the potential to... Via Benzinga Cybin Releases Q2 Financial Results November 15, 2021 Cybin (NYSE: Via Benzinga Cybin to Release Q2 2021 Results on November 15 November 09, 2021 Cybin (NYSE: Via Benzinga Cybin Inc. Receives Schedule I Manufacturing License from DEA November 04, 2021 Cybin (NYSE: Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021 November 19, 2021 Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE: Via Benzinga Cybin Reports Q2 Financial Results And Latest News, Including FDA & DEA Research Approvals November 15, 2021 Toronto-based, Cybin Inc. (NEO: CYBN) (NYSE: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics,” reported its unaudited... Via Benzinga Exposures Product Safety Psychedelic Drug Stocks Have Plunged -10.6%, On Average, So Far In November November 14, 2021 Our Pure-Play Psychedelic Compounds-Based Drug Stocks Index has declined -10.6% in the last 2 weeks; it's still up +7.8% since the end of September. Via Talk Markets Can The Psychedelics Boom Go Bust? A Conversation With Cybin Chief Clinical Officer Dr. Alex Belser November 14, 2021 This article was originally published on Psychedelic Spotlight and appears here with permission. "Something that people used t... Via Benzinga Compass Pathways Phase II Results: A Disappointment For Some, An Opportunity For Others November 11, 2021 Compass Pathways reported Via Talk Markets Cybin Unveils Data Suggesting Its Novel Psilocybin Analog Is the 'Superior Molecule' November 11, 2021 This article was originally published on Via Benzinga Cybin CEO Presenting at Jefferies London Healthcare Conference November 11, 2021 Cybin (NYSE: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” has announced that its CEO Doug Drysdale will present at the... Via Benzinga Compass Pathways Goes On Bad Trip, Despite 'Positive' Results From Psilocybin Trial November 09, 2021 Shares plunged, despite a psilocybin-based drug reducing depression in a trial. Via Investor's Business Daily 32 Stocks Moving in Tuesday's Pre-Market Session November 09, 2021 Gainers Dover Motorsports, Inc. (NYSE: DVD) rose 57% to $3.58 in pre-market trading. Luminar Technologies, Inc. (NASDAQ: LAZR) rose 54.2% to $26.98 in pre-market trading after... Via Benzinga Cybin Announces Positive Data Showing Effectiveness of Psilocybin To Treat Depression November 08, 2021 Cybin Inc (NYSE: CYBN), a Toronto-based biotechnology company focused on utilizing psychedelic drugs as an alternative to traditional psychiatric drugs, announced positive... Via Benzinga 64 Biggest Movers From Yesterday November 09, 2021 Gainers Pioneer Power Solutions, Inc. (NASDAQ: PPSI) shares jumped 219% to close at $10.40 on Monday after the company announced the launch of its E-Boost portfolio of mobile... Via Benzinga Cybin's CYB003 Demonstrates Advantages over Oral Psilocybin for Mental Health November 08, 2021 Cybin (NYSE: Via Benzinga Psyched: Detroit Decriminalizes Psychedelics, Compass To Study Psilocybin For PTSD, Filaments Gets First-Ever FDA Approval November 08, 2021 Detroit Decriminalizes Psychedelics Via Benzinga Exposures Product Safety Cybin Gets DEA License To Work With Scheduled Psychedelic Molecules November 04, 2021 Cybin Inc. (NYSE:CYBN) a company developing novel psychedeli... Via Benzinga Cybin Inc. Schedules R&D Briefing to Release Breakthrough Research Findings November 02, 2021 Cybin (NEO: CYBN) (NYSE: Via Benzinga Psyched: MindMed's MDMA Program For Autism, Small Pharma's New Patent, NovaMentis' Orphan Drug Designation November 01, 2021 The Week In Psychedelics: Via Benzinga Topics Intellectual Property Exposures Intellectual Property Cybin: FDA Authorizes Feasibility Study To Measure Ketamine's Effect On Cerebral Cortex October 27, 2021 Cybin Inc. (NEO: CYBN) (NYSE: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, announced Wednesday that the U.S. Food and Drug Administration (FDA)... Via Benzinga Exposures Product Safety Cybin Inc. Announces FDA IND Authorization of Potentially Pivotal Study October 27, 2021 Cybin (NYSE: Via Benzinga Exposures Product Safety Psyched: British PM Considers Psychedelics, New Partnership To Study Psilocybin For Autism, Compass Gets Another Patent October 26, 2021 The Week In Psychedelics Via Benzinga Psychedelics Industry Moving Full-Speed Ahead, When Will Stocks Catch Up? October 23, 2021 The psychedelic drug industry is advancing by leaps and bounds, but the stocks have been sliding. Why this disconnect won't last. Via Talk Markets Psychedelics Discussed At Benzinga Cannabis Capital Conference: Growth Opportunities, Mental Health & Pharma October 19, 2021 Ronan Levy, co-founder and executive chairman of Field Trip Ltd (NASDAQ: FTRP), a company developing a network of psychedelics-assisted therapy clinics; Doug Drysdale, CEO,... Via Benzinga Topics Cannabis Exposures Cannabis Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation October 18, 2021 The Week In Psychedelics Via Benzinga < Previous 1 2 ... 14 15 16 17 18 19 20 21 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.